Literature DB >> 2969953

Continuous subcutaneous lisuride infusions in Parkinson's disease.

P H Critchley1, F Grandas Perez, N P Quinn, J D Parkes, C D Marsden.   

Abstract

Thirteen patients with idiopathic Parkinson's disease and "on-off" fluctuations on oral levodopa plus dopa decarboxylase inhibitor (DDI) were treated with continuous (24 hour) subcutaneous lisuride infusions together with a reduced dose of levodopa (plus DDI). An improvement in motor performance was seen in 10 patients, with a mean increase in percentage of waking time spent "on" of 32 per cent (range 13-59 percent). However, adverse effects were common, especially psychiatric effects, leading to treatment withdrawal in 11 of 13 subjects after a mean of 40 days' treatment. Continuous lisuride infusion together with a small dose of levodopa (plus DDI) are effective treatment for "on-off" fluctuations in Parkinson's disease, but the frequency of adverse effects limits the number of patients who can be treated successfully with this technique.

Entities:  

Mesh:

Substances:

Year:  1988        PMID: 2969953     DOI: 10.1007/978-3-7091-8954-2_6

Source DB:  PubMed          Journal:  J Neural Transm Suppl        ISSN: 0303-6995


  2 in total

Review 1.  A risk-benefit assessment of drugs used in the management of Parkinson's disease.

Authors:  I Y Bodagh; D R Robertson
Journal:  Drug Saf       Date:  1994-08       Impact factor: 5.606

2.  Continuous subcutaneous lisuride infusion in OPCA.

Authors:  A Heinz; J Wöhrle; L Schöls; P Klotz; W Kuhn; H Przuntek
Journal:  J Neural Transm Gen Sect       Date:  1992
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.